233 related articles for article (PubMed ID: 8126059)
41. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
[TBL] [Abstract][Full Text] [Related]
42. Endocrine and antitumoral effects of R76713 in rats.
De Coster R; Van Ginckel R; Wouters W; Goeminne N; Vanherck W; Byloos M
J Enzyme Inhib; 1990; 4(2):159-67. PubMed ID: 2098522
[TBL] [Abstract][Full Text] [Related]
43. Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Dao B; Vanage G; Li XJ; Bardin CW; Koide SS
Contraception; 1997 Jan; 55(1):35-40. PubMed ID: 9013059
[TBL] [Abstract][Full Text] [Related]
44. A potent specific pure antiestrogen with clinical potential.
Wakeling AE; Dukes M; Bowler J
Cancer Res; 1991 Aug; 51(15):3867-73. PubMed ID: 1855205
[TBL] [Abstract][Full Text] [Related]
45. Systemic ICI 182,780 alters the display of sexual behaviors in the female rat.
Gardener HE; Clark AS
Horm Behav; 2001 Mar; 39(2):121-30. PubMed ID: 11243740
[TBL] [Abstract][Full Text] [Related]
46. Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat.
Dipippo VA; Powers CA
J Pharmacol Exp Ther; 1997 Apr; 281(1):142-8. PubMed ID: 9103491
[TBL] [Abstract][Full Text] [Related]
47. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
48. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
Coopman P; Garcia M; Brünner N; Derocq D; Clarke R; Rochefort H
Int J Cancer; 1994 Jan; 56(2):295-300. PubMed ID: 8314314
[TBL] [Abstract][Full Text] [Related]
49. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models.
Schneider MR; Michna H; Nishino Y; el Etreby MF
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):783-7. PubMed ID: 2285591
[TBL] [Abstract][Full Text] [Related]
50. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of estrogen and antiestrogen action in mammary cancer.
Katzenellenbogen BS; Rorke EA; Eckert RL
J Steroid Biochem; 1981 Dec; 15():219-29. PubMed ID: 7339248
[No Abstract] [Full Text] [Related]
52. Differential spatiotemporal regulation of lactoferrin and progesterone receptor genes in the mouse uterus by primary estrogen, catechol estrogen, and xenoestrogen.
Das SK; Tan J; Johnson DC; Dey SK
Endocrinology; 1998 Jun; 139(6):2905-15. PubMed ID: 9607801
[TBL] [Abstract][Full Text] [Related]
53. Effects of onapristone, tamoxifen and ICI 182780 on uterine prostaglandin production and luteal function in nonpregnant guinea-pigs.
Poyser NL
J Reprod Fertil; 1993 May; 98(1):307-12. PubMed ID: 8345476
[TBL] [Abstract][Full Text] [Related]
54. The display of sexual behaviors by female rats administered ICI 182,780.
Clark AS; Guarraci FA; Megroz AB; Porter DM; Henderson LP
Horm Behav; 2003 Apr; 43(4):454-64. PubMed ID: 12788291
[TBL] [Abstract][Full Text] [Related]
55. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
56. Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice.
Gutman M; Couillard S; Labrie F; Candas B; Labrie C
Cancer Res; 1999 Oct; 59(20):5176-80. PubMed ID: 10537294
[TBL] [Abstract][Full Text] [Related]
57. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
58. The prostate growth stimulation by progesterone is due to androgenic products and progesterone receptor-mediated mechanisms.
Nishino T; Ishibashi K; Hirtreiter C; Nishino Y
Pharmazie; 2009 Sep; 64(9):587-9. PubMed ID: 19827300
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Labrie F; Li S; Labrie C; Lévesque C; Mérand Y
Breast Cancer Res Treat; 1995 Mar; 33(3):237-44. PubMed ID: 7749151
[TBL] [Abstract][Full Text] [Related]
60. High inhibitory activity of a new antiestrogen, RU 16117 (11alpha-methoxy ethinyl estradiol), on the development of dimethylbenz(a)anthracene-induced mammary tumors.
Kelly PA; Asselin J; Caron MG; Raynaud JP; Labrie F
Cancer Res; 1977 Jan; 37(1):76-81. PubMed ID: 187338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
